2023 ´ëÇÑÇ÷¾×ÇÐȸ Ãß°èÇмú´ëȸ : 2023-11-03
±³À°ÀÏÀÚ : 2023-11-03
±³À°Àå¼Ò : ¼¿ï·Ôµ¥È£ÅÚ
±³À°ÁÖÁ¦ : 2023 ´ëÇÑÇ÷¾×ÇÐȸ Ãß°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ : hematology@kams.or.kr
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀÎ : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í Àü¹®ÀÇ 50,000¿ø / Àü°øÀÇ 20,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11¿ù 03ÀÏ ROOM A 10:00~10:30 Recent updates on polycythemia vera and essential thrombocythemia ÃÖÀ±¼÷(¿ï»êÀÇ´ë )
±³À°½Ã°£ 11¿ù 03ÀÏ ROOM A 10:30~11:00 Recent updates on primary and secondary myelofibrosis À̼¼·Ã(°í·ÁÀÇ´ë )
±³À°½Ã°£ 11¿ù 03ÀÏ ROOM A 11:00~11:30 Genomic analysis in CML(chronic myeloid leukemia): BCR-ABL and other mutations ¹®ÁØÈ£(°æºÏÀÇ´ë )
±³À°½Ã°£ 11¿ù 03ÀÏ ROOM A 11:30~12:00 Single cell genomics in CML(chronic myeloid leukemia) Á¶¿µ¿í(¿ï»êÀÇ´ë )
±³À°½Ã°£ 11¿ù 03ÀÏ ROOM A 13:00~13:30 Microbiome analysis for the development of risk-adapted treatment strategy for lymphoma patients À±»óÀº(¼º±Õ°üÀÇ´ë )
±³À°½Ã°£ 11¿ù 03ÀÏ ROOM A 13:30~14:00 Translational research with patients-derived extracellular vesicles in hematologic malignancy °°¡¿ø(°í·ÁÀÇ´ë )
±³À°½Ã°£ 11¿ù 03ÀÏ ROOM A 14:00~14:30 The role of cytogenetic testing by fluorescence in situ hybridization in lymphoid malignancy Á¶Çö¼ö(¿¬¼¼ÀÇ´ë )
±³À°½Ã°£ 11¿ù 03ÀÏ ROOM A 14:30~15:00 How to conduct a meta-analysis for the reaserch of hematologic malignancy ±èÁøö(ÀÎÇÏÀÇ´ë )
±³À°½Ã°£ 11¿ù 03ÀÏ ROOM B 15:30~16:00 Biologic mechanism of factor VIII and IX physiology ¾È¿ø±â(¿¬¼¼ÀÇ´ë )
±³À°½Ã°£ 11¿ù 03ÀÏ ROOM B 16:00~16:30 On-demant treatment and perioperative management ÇÑÀçÁØ(°æÈñÀÇ´ë )
±³À°½Ã°£ 11¿ù 03ÀÏ ROOM B 16:30~17:00 Proper prophylaxis for hemophilia A and B ¹ÚÁ¤¾Æ(ÀÎÇÏÀÇ´ë )
±³À°½Ã°£ 11¿ù 03ÀÏ ROOM B 17:00~17:30 The use of non-factor treatment for hemophilia treatment ÃÖ¿µ¹è(¾ÆÁÖÀÇ´ë )